SCHEMBL6214922

SCHEMBL6214922

CC(C)(C)OC(=O)NC(=N)c1ccc2c(c1)C(CCNC(=O)C(C)(c1ccccc1)c1ccccc1)CO2

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.38
HTR1D P28221 1/20 0.38
HTR2C P28335 1/20 0.38
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
LMNA P02545 1/20 0.36
FFAR1 O14842 4/20 0.36
PPARG P37231 3/20 0.36
PPARD Q03181 3/20 0.36
LTB4R Q15722 2/20 0.34
LTB4R2 Q9NPC1 2/20 0.34
TBXA2R P21731 3/20 0.33
TBXAS1 P24557 2/20 0.33
IDO1 P14902 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6242842 0.85 HTR1A (0.40) HTR1AHTR1DHTR2CLMNAFFAR1
SCHEMBL6215027 0.85 CHRM4 (0.41) TBXA2R
SCHEMBL2640170 0.85 HTR1A (0.47) HTR1AHTR1DHTR2CCNR1CNR2
SCHEMBL6211980 0.84 RAB9A (0.38) HTR1AHTR1DHTR2CFFAR1PPARG
SCHEMBL7221563 0.83 HPGD (0.46) LMNA
SCHEMBL6213032 0.83 MAPT (0.41) HTR1AHTR1DHTR2CLMNAPPARG
SCHEMBL6213925 0.82 HTR1A (0.38) HTR1AHTR1DHTR2CTBXA2R
SCHEMBL6213310 0.82 TBXA2R (0.37) HTR1AHTR1DHTR2CLMNATBXA2R
SCHEMBL6212619 0.82 CHRM4 (0.46) FFAR1
SCHEMBL6216526 0.82 TBXA2R (0.42) HTR1AHTR1DHTR2CTBXA2RTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1222182-B1 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS AVENTIS PHARMA INC (US) 2005-11-16 EP disclosed
US-6599918-B2 Inhibit Factor Xa Factor IIa (thrombin) AVENTIS PHARMACEUTICALS INC. 2003-07-29 US disclosed
US-20020193410-A1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans AVENTIS PHARMACEUTICALS INC. 2002-12-19 US disclosed
EP-1222182-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS Aventis Pharmaceuticals Inc. (US) 2002-07-17 EP disclosed
WO-2001014358-A2 SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS AVENTIS PHARMACEUTICALS INC. (DE) 2001-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193410-A1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans F2, TFPI, F3 HTR1A 1462/4885HTR1D 2054/4885HTR2C 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.